Effects of Anti-VEGF Targeted Drugs on Patients' Blood Pressure and Endothelial Function

Peking University Third Hospital30 enrolled

Overview

Explore the effects of anti-VEGF targeted drugs on blood pressure and endothelial function in cancer patients.

Thirty tumor patients with anti-VEGF drugs were selected. Demographic information and clinical information of all patients were collected before chemotherapy. Ambulatory blood pressure monitoring and endothelial function measurement (PWV, EndoPAT) were performed. Ambulatory blood pressure and PWV were reviewed at 2 weeks and 1 month. And EndoPAT, to evaluate the effects of anti-VEGF drugs on blood pressure and endothelial function in cancer patients.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Cardiac Toxicity VEGF Endothelial Dysfunction

Interventions

Anti-VEGFDRUG

Anti-tumor drugs targeting the vascular endothelial growth factor (VEGF) signaling pathway

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Tumor patients using anti-VEGF drugs Exclusion Criteria: * Hypertension, coronary heart disease, valvular heart disease, cardiomyopathy and other organic heart diseases, exclude liver and kidney failure, severe cerebrovascular disease, chronic obstructive pulmonary disease, rheumatic immune system disease

Locations (1)

Peking University Third Hospital

Beijing, Beijing Municipality, China

RECRUITING

Outcomes

Primary Outcomes

Time ending

30 days after using the Anti-VEGF Targeted Drugs

Time frame: 1 month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.